•  
  •  
 

Document Type

Original Article

Abstract

Background: Endometrial hyperplasia is a probable precursor to endometrial cancer and a main cause of severe abnormal bleeding. Recently, metformin has been proposed as an adjunctive medicine for improved outcome in treating EH. Metformin has been shown to have anticancer efficacy by reducing cell proliferation and slowing tumor growth, according to recent studies. Aim and objectives: to compare between progestin versus metformin and progestin in treatment of endometrial hyperplasia without atypia in premenopausal females. Subjects & methods This comparative randomized controlled experiment was conducted at Al-Hussein University Hospital, obstetrics and gynecology department on 60 premenopausal women diagnosed by endometrial hyperplasia without atypia divided into 2 groups: (group 1); included 30 women took progestin for 6 months then endometrial biopsy was taken after treatment, (group 2); included 30 women took metformin and progestin for 6 months then endometrial biopsy was taken after treatment. Results: Both the ET results after treatment, and the Pathology results both before and after therapy, were significantly different among the 2 groups. There were no significant difference between both groups as regard Age distribution, Parity distribution, Sonographic Endometrial Thickness (mm) before treatment and Blood sugar before and after treatment. Conclusion: According to our results, we found that Metformin in combination with progestin has better effects in treating endometrial hyperplasia more than progestin alone with less adverse effects. Further studies are needed to confirm our results.

Keywords

Endometrial hyperplasia; Atypia; Progestin; Metformin; premenopausal women.

Subject Area

Obstetrics and Gynecology

Download

Share

COinS